Back to News
Market Impact: 0.2
Jefferies Upgrades Summit Therapeutics to Buy from Hold
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Jefferies upgraded Summit Therapeutics (NASDAQGM:SMMT) to Buy from Hold on September 9, 2026, reversing its March 16 downgrade from Buy to Hold. The rating change is a positive analyst signal for the biotech company, though the report provides no price target, financial data, or underlying rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
SMMT0.50
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Goldman says these top tech stocks have plenty of upside ahead of earnings
- ProPetro’s 49% decline: how Fair Value spotted the warning signs
- Persistent Oil Prices Threaten Inflation Outlook
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Could France’s debt crisis spread across Europe?